https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
Moreover, we have also evaluated the impact of Sn-In2O3 NPs on human colorectal carcinoma cells (HCT-116). The results demonstrated that Sn-In2O3 NPs (Sn/In = 5%, 10% and 15%), caused dose dependent decrease in the cancer cell viability as the low dosage (2.0 mg/mL) showed 62.11% cell viability, while 4.0, 8.0, 16.0, 32.0 mg/mL dosages showed 20.45%, 18.25%, 16.58%, and 15.58% cell viability. In addition, the treatment of Sn-In2O3 NPs also showed significant cellular and anatomical changes in cancer cells as examined b
Beğen
Yorum Yap
Paylaş
